vs
IMAX（IMAX）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是IMAX的1.0倍（$127.1M vs $125.2M），IMAX同比增速更快（35.1% vs 17.1%），IMAX自由现金流更多（$28.0M vs $-26.7M），过去两年IMAX的营收复合增速更高（25.8% vs 20.8%）
IMAX公司是加拿大的影视放映技术企业，1967年创立于蒙特利尔，总部位于多伦多地区，在纽约、洛杉矶均设有业务点。核心业务包括IMAX摄影机与放映系统的设计制造，同时面向全球合作影院提供影片开发、制作、后期及发行服务，是沉浸式观影技术领域的领先企业。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
IMAX vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.0倍
$125.2M
营收增速更快
IMAX
高出18.0%
17.1%
自由现金流更多
IMAX
多$54.7M
$-26.7M
两年增速更快
IMAX
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $125.2M | $127.1M |
| 净利润 | $637.0K | — |
| 毛利率 | 57.6% | 51.0% |
| 营业利润率 | 19.3% | -54.6% |
| 净利率 | 0.5% | — |
| 营收同比 | 35.1% | 17.1% |
| 净利润同比 | -88.0% | — |
| 每股收益（稀释后） | $0.02 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IMAXZLAB
| Q4 25 | $125.2M | $127.1M | ||
| Q3 25 | $106.7M | $115.4M | ||
| Q2 25 | $91.7M | $109.1M | ||
| Q1 25 | $86.7M | $105.7M | ||
| Q4 24 | $92.7M | $108.5M | ||
| Q3 24 | $91.5M | $101.8M | ||
| Q2 24 | $89.0M | $100.1M | ||
| Q1 24 | $79.1M | $87.1M |
净利润IMAXZLAB
| Q4 25 | $637.0K | — | ||
| Q3 25 | $20.7M | $-36.0M | ||
| Q2 25 | $11.3M | $-40.7M | ||
| Q1 25 | $2.3M | $-48.4M | ||
| Q4 24 | $5.3M | — | ||
| Q3 24 | $13.9M | $-41.7M | ||
| Q2 24 | $3.6M | $-80.3M | ||
| Q1 24 | $3.3M | $-53.5M |
毛利率IMAXZLAB
| Q4 25 | 57.6% | 51.0% | ||
| Q3 25 | 63.1% | 59.5% | ||
| Q2 25 | 58.5% | 60.6% | ||
| Q1 25 | 61.4% | 63.6% | ||
| Q4 24 | 52.2% | 61.5% | ||
| Q3 24 | 55.8% | 64.1% | ||
| Q2 24 | 49.4% | 64.9% | ||
| Q1 24 | 59.3% | 61.4% |
营业利润率IMAXZLAB
| Q4 25 | 19.3% | -54.6% | ||
| Q3 25 | 27.2% | -42.3% | ||
| Q2 25 | 15.6% | -50.3% | ||
| Q1 25 | 19.3% | -53.3% | ||
| Q4 24 | 10.3% | -62.6% | ||
| Q3 24 | 21.2% | -66.6% | ||
| Q2 24 | 3.2% | -76.0% | ||
| Q1 24 | 15.3% | -80.7% |
净利率IMAXZLAB
| Q4 25 | 0.5% | — | ||
| Q3 25 | 19.4% | -31.2% | ||
| Q2 25 | 12.3% | -37.3% | ||
| Q1 25 | 2.7% | -45.8% | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 15.2% | -40.9% | ||
| Q2 24 | 4.0% | -80.2% | ||
| Q1 24 | 4.1% | -61.4% |
每股收益（稀释后）IMAXZLAB
| Q4 25 | $0.02 | $-0.05 | ||
| Q3 25 | $0.37 | $-0.03 | ||
| Q2 25 | $0.20 | $-0.04 | ||
| Q1 25 | $0.04 | $-0.04 | ||
| Q4 24 | $0.09 | $-0.09 | ||
| Q3 24 | $0.26 | $-0.04 | ||
| Q2 24 | $0.07 | $-0.08 | ||
| Q1 24 | $0.06 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $151.2M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $337.9M | $715.5M |
| 总资产 | $894.0M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IMAXZLAB
| Q4 25 | $151.2M | $689.6M | ||
| Q3 25 | $143.1M | $717.2M | ||
| Q2 25 | $109.3M | $732.2M | ||
| Q1 25 | $97.1M | $757.3M | ||
| Q4 24 | $100.6M | $779.7M | ||
| Q3 24 | $104.5M | $616.1M | ||
| Q2 24 | $91.6M | $630.0M | ||
| Q1 24 | $81.0M | $650.8M |
股东权益IMAXZLAB
| Q4 25 | $337.9M | $715.5M | ||
| Q3 25 | $349.5M | $759.9M | ||
| Q2 25 | $320.4M | $791.7M | ||
| Q1 25 | $299.5M | $810.8M | ||
| Q4 24 | $299.5M | $840.9M | ||
| Q3 24 | $289.4M | $667.7M | ||
| Q2 24 | $267.2M | $704.2M | ||
| Q1 24 | $258.8M | $762.2M |
总资产IMAXZLAB
| Q4 25 | $894.0M | $1.2B | ||
| Q3 25 | $889.6M | $1.2B | ||
| Q2 25 | $868.6M | $1.2B | ||
| Q1 25 | $848.3M | $1.2B | ||
| Q4 24 | $830.4M | $1.2B | ||
| Q3 24 | $847.6M | $985.3M | ||
| Q2 24 | $827.4M | $987.4M | ||
| Q1 24 | $824.1M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $29.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $28.0M | $-26.7M |
| 自由现金流率自由现金流/营收 | 22.3% | -21.0% |
| 资本支出强度资本支出/营收 | 1.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 46.11× | — |
| 过去12个月自由现金流最近4个季度 | $118.9M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流IMAXZLAB
| Q4 25 | $29.4M | $-26.0M | ||
| Q3 25 | $67.5M | $-32.0M | ||
| Q2 25 | $23.2M | $-31.0M | ||
| Q1 25 | $7.0M | $-61.7M | ||
| Q4 24 | $11.5M | $-55.8M | ||
| Q3 24 | $35.3M | $-26.8M | ||
| Q2 24 | $35.0M | $-42.2M | ||
| Q1 24 | $-11.0M | $-90.1M |
自由现金流IMAXZLAB
| Q4 25 | $28.0M | $-26.7M | ||
| Q3 25 | $64.8M | $-35.0M | ||
| Q2 25 | $20.9M | $-33.9M | ||
| Q1 25 | $5.3M | $-63.2M | ||
| Q4 24 | $6.9M | $-58.4M | ||
| Q3 24 | $34.2M | $-28.2M | ||
| Q2 24 | $33.5M | $-42.9M | ||
| Q1 24 | $-12.1M | $-91.1M |
自由现金流率IMAXZLAB
| Q4 25 | 22.3% | -21.0% | ||
| Q3 25 | 60.7% | -30.4% | ||
| Q2 25 | 22.8% | -31.1% | ||
| Q1 25 | 6.1% | -59.9% | ||
| Q4 24 | 7.4% | -53.8% | ||
| Q3 24 | 37.3% | -27.7% | ||
| Q2 24 | 37.6% | -42.9% | ||
| Q1 24 | -15.3% | -104.5% |
资本支出强度IMAXZLAB
| Q4 25 | 1.1% | 0.5% | ||
| Q3 25 | 2.6% | 2.6% | ||
| Q2 25 | 2.6% | 2.6% | ||
| Q1 25 | 1.9% | 1.5% | ||
| Q4 24 | 5.0% | 2.4% | ||
| Q3 24 | 1.2% | 1.3% | ||
| Q2 24 | 1.8% | 0.7% | ||
| Q1 24 | 1.4% | 1.1% |
现金转化率IMAXZLAB
| Q4 25 | 46.11× | — | ||
| Q3 25 | 3.27× | — | ||
| Q2 25 | 2.06× | — | ||
| Q1 25 | 2.99× | — | ||
| Q4 24 | 2.16× | — | ||
| Q3 24 | 2.54× | — | ||
| Q2 24 | 9.78× | — | ||
| Q1 24 | -3.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
